F D C Ltd
FDCF D C Ltd
FDC
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.52 | 3.23 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.31 | 5.09 | 0.71% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
FDC Limited is a pharmaceutical company engaged in manufacture of specialized formulations, and oral rehydration salts (ORS). Its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 935.01 | 1,032.86 | 1,064.15 | 1,126.03 | 1,134.17 | 1,413.09 | 1,430.24 | 1,604.01 | 1,833.61 | 1,948.97 | ||||||||||
Raw Materials | 347.21 | 363.25 | 340.29 | 354.77 | 367.29 | 420.53 | 440.17 | 595.64 | 670.93 | 1,570.22 | ||||||||||
| Power & Fuel Cost | 20.18 | 23.14 | 21.55 | 22.00 | 24.61 | 27.40 | 27.08 | 28.92 | 34.12 | |||||||||||
| Employee Cost | 137.58 | 175.76 | 191.08 | 216.67 | 225.57 | 277.48 | 296.29 | 343.33 | 390.90 | |||||||||||
| Selling & Administrative Expenses | 106.74 | 108.33 | 117.71 | 137.51 | 138.37 | 160.43 | 156.64 | 234.10 | 289.12 | |||||||||||
| Operating & Other expenses | 79.04 | 95.11 | 105.66 | 117.91 | 107.01 | 166.41 | 81.10 | 72.24 | 147.71 | |||||||||||
EBITDA | 244.26 | 267.27 | 287.86 | 277.17 | 271.32 | 360.84 | 428.96 | 329.78 | 300.83 | 378.75 | ||||||||||
| Depreciation/Amortization | 38.81 | 33.73 | 34.62 | 35.14 | 33.24 | 37.46 | 37.81 | 37.30 | 38.94 | 39.10 | ||||||||||
| PBIT | 205.45 | 233.54 | 253.24 | 242.03 | 238.08 | 323.38 | 391.15 | 292.48 | 261.89 | 339.65 | ||||||||||
| Interest & Other Items | 1.81 | 1.40 | 1.41 | 1.40 | 1.44 | 3.42 | 3.43 | 3.09 | 4.09 | 4.47 | ||||||||||
| PBT | 203.64 | 232.14 | 251.83 | 240.63 | 236.64 | 319.96 | 387.72 | 289.39 | 257.80 | 335.18 | ||||||||||
| Taxes & Other Items | 55.50 | 63.47 | 63.30 | 67.12 | 66.84 | 80.07 | 86.37 | 72.99 | 63.76 | 84.00 | ||||||||||
| Net Income | 148.14 | 168.67 | 188.53 | 173.51 | 169.80 | 239.89 | 301.35 | 216.40 | 194.04 | 251.18 | ||||||||||
| EPS | 8.19 | 9.32 | 10.42 | 9.68 | 9.56 | 13.77 | 17.74 | 12.82 | 11.59 | 15.14 | ||||||||||
| DPS | 2.25 | 2.25 | 2.25 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.27 | 0.24 | 0.22 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| F D C Ltd | 33.03 | 3.23 | — |
| Sun Pharmaceutical Industries Ltd | 34.71 | 4.96 | 0.94% |
| Cipla Ltd | 34.93 | 4.13 | 0.70% |
| Dr Reddy's Laboratories Ltd | 21.38 | 4.14 | 0.69% |
Price Comparison
Compare FDC with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding F D C Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India SMALL CAP FUND DIRECT PLAN GROWTH PLAN GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.4097% | Percentage of the fund’s portfolio invested in the stock 0.41% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/214 (0) |
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.5985% | Percentage of the fund’s portfolio invested in the stock 3.13% | Change in the portfolio weight of the stock over the last 3 months -1.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/55 (-3) |
ICICI Prudential Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8615% | Percentage of the fund’s portfolio invested in the stock 0.91% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/94 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹0.80
Ex DateEx Date
Mar 19, 2020
Cash Dividend
Ex DateEx DateAug 8, 2017
Dividend/Share
₹2.25
Ex DateEx Date
Aug 8, 2017
Cash Dividend
Ex DateEx DateMar 17, 2016
Dividend/Share
₹2.25
Ex DateEx Date
Mar 17, 2016
Cash Dividend
Ex DateEx DateSep 23, 2015
Dividend/Share
₹2.25
Ex DateEx Date
Sep 23, 2015
Cash Dividend
Ex DateEx DateJul 28, 2014
Dividend/Share
₹2.25
Ex DateEx Date
Jul 28, 2014
News & Opinions
Aurobindo Pharma’s generic FDC drug to treat children living with HIV gets U.S. FDA’s tentative nod
3 months ago•The Hindu
FDC Stock Hits Record High After Q1 Profit Jumps, Board Approves Share Buyback
3 months ago•Bloomberg Quint
FDC Ban Latest News: Govt planning more crackdowns on vitamin and mineral combination drugs
5 months ago•Business Standard
Chart Focus: BSE Healthcare Index Shows Bullish Reversal, Points to Potential Rally
5 months ago•The Hindu Businessline
Delhi HC Seeks Centre’s Stand on Challenge to Ban on Fixed Dose Combination Drugs - News18
5 months ago•News18
Breakout Stocks: How are FDC, Suzlon Energy and Go Fashion looking on charts for Tuesday
5 months ago•Economic Times
‘Ban on 14 FDC drugs unlikely to impact consumers’
5 months ago•The Hindu Businessline
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.24%, vs industry avg of 8.45%
Increasing Market Share
Over the last 5 years, market share increased from 0.55% to 0.57%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 2.26%, vs industry avg of 9.82%